NASDAQ:XLO Xilio Therapeutics Q3 2024 Earnings Report $9.05 +0.01 (+0.11%) Closing price 04:00 PM EasternExtended Trading$9.05 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Xilio Therapeutics EPS ResultsActual EPS-$3.08Consensus EPS -$3.50Beat/MissBeat by +$0.42One Year Ago EPSN/AXilio Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AXilio Therapeutics Announcement DetailsQuarterQ3 2024Date11/7/2024TimeBefore Market OpensConference Call DateThursday, November 7, 2024Conference Call Time9:00AM ETUpcoming EarningsXilio Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Xilio Therapeutics Earnings HeadlinesXilio Names Yariv Houvras Chief Medical OfficerSeptember 28 at 3:19 PM | rttnews.comXilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical OfficerSeptember 28 at 10:19 AM | markets.businessinsider.comManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 in one quarter. Institutions own about 83% of shares, including BlackRock's 32 million shares worth $716 million and Vanguard's 48 million shares worth nearly $1.1 billion. A new multi-year deal with Palantir adds an AI-driven edge to this energy producer's operations.September 28 at 1:00 AM | Monument Traders Alliance (Ad)Xilio Therapeutics Appoints Yariv J. Houvras, M.D.September 28 at 7:30 AM | globenewswire.comReviewing Xilio Therapeutics (NASDAQ:XLO) and Rigel Pharmaceuticals (NASDAQ:RIGL)September 20, 2026 | americanbankingnews.comXilio Therapeutics Grants Inducement Stock Options to New Employees Under 2022 PlanSeptember 2, 2026 | quiverquant.comQSee More Xilio Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xilio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xilio Therapeutics and other key companies, straight to your email. Email Address About Xilio TherapeuticsXilio Therapeutics (NASDAQ:XLO) is a clinical-stage biotechnology company focused on developing tumor-activated immunotherapies for the treatment of cancer. The company’s approach is designed to activate therapeutic agents selectively within the tumor microenvironment, with the goal of stimulating an immune response against cancer while reducing exposure to healthy tissues and the systemic side effects associated with conventional immunotherapies. Xilio’s product candidates are based on its proprietary tumor-activation technology and include engineered cytokines and immune-oncology antibodies. Its development programs have included tumor-activated versions of interleukin-2, interleukin-12 and anti-CTLA-4 therapies. These candidates are being investigated for potential use in solid tumors, both as standalone treatments and in combination with other cancer therapies. Headquartered in Waltham, Massachusetts, Xilio Therapeutics was founded in 2015 and became a publicly traded company on the Nasdaq under the symbol XLO in 2021. The company’s activities are primarily focused on research, clinical development and advancing its pipeline of oncology medicines through clinical testing and potential strategic partnerships.View Xilio Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum2 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindFertilizer Prices Keep Climbing: 3 Stocks Still Trading at a Discount Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
